Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
"Denmark's economy runs on Novo
Factors such as the desired degree of weight loss, glycemic control goals, and cost considerations play a role in determining the most suitable treatment
Initially prescribed for type-2 diabetes patients to enhance glycemic control, semaglutide has proven efficacy in weight loss through numerous clinical studies
So far the only people who might qualify to get insurance coverage for FDA-approved Ozempic and Wegovy are those who meet national guidelines which include, a BMI of 27 or above with a metabolic comorbidity such as diabetes, high blood pressure, high cholesterol, sleep apnea, and heart disease, or a BMI 30 or above without any other comorbidities, Narang explained
Nonetheless, any new or worsening symptom during treatment warrants clinical evaluation to determine appropriate management
This leads to reduced caloric intake and, consequently, weight loss
